Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 256-262

  Schroen, Anneke T ^a,b   Petroni, Gina R ^b   Wang, Hongkun ^b   Thielen, Monika J ^a   Gray, Robert ^c   Benedetti, Jacqueline ^d   Wang, Xiaofei F ^e   Sargent, Daniel J ^f   Wickerham, Donald L ^g   Cronin, Walter ^g   Djulbegovic, Benjamin ^h   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g NSABP Foundation Inc   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; EARLY TERMINATION OF CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; UNITED STATES;

EID: 84855461394     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1633     Document Type: Article

References (19)

1. Institute of Medicine. A national cancer clinical trials system for the 21st century: reinvigorating the NCI cooperative group program. Washington, DC: IOM (Institute of Medicine) The National Academies Press; 2010.
2. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010;16:5557-63.
3. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of national cancer institute cooperative group phase III trials activated from 2000 to 2007. J Clin Oncol 2010;28:5197-201.
4. Hopewell S, Clarke MJ, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database Syst Rev 2007;MR000011.
5. Collins JF, Williford WO, Weiss DG, Bingham SF, Klett CJ. Planning patient recruitment: fantasy and reality. Stat Med 1984;3:435-43. (Pubitemid 15167915)
6. Vale C, Stewart L, Tierney J. UK Coordinating Committee for Cancer Research National Register of Cancer. Trends in UK cancer trials: results from the UK coordinating committee for cancer research national register of cancer trials. Br J Cancer 2005;92:811-4. (Pubitemid 40462622)
7. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9.
8. Charlson ME, Horwitz RI. Applying results of randomised trials to clinical practice: Impact of losses before randomisation. Br Med J (Clin Res Ed) 1984;289:1281-4. (Pubitemid 15217616)
9. Ramsey S, Scoggins J. Commentary: practicing on the tip of an information iceberg? evidence of underpublication of registered clinical trials in oncology. Oncologist 2008;13:925-9.
10. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010;153:158-66.
11. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64.
12. Doroshow JH, Hortobagyi G, Operational Working Group of the Clinical Trials and Translational Research Advisory Committee. Compressing the timeline for cancer clinical trial activation. Bethesda (MD): National Cancer Institute; 2010.
13. Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, Wu AY, et al. Steps and time to process clinical trials at the cancer therapy evaluation program. J Clin Oncol 2009;27:1761-6.
14. Doroshow JH;Clinical Trials Working Group of the National Cancer Advisory Board. Restructuring the national cancer clinical trials enterprise. Bethesda, MD: National Cancer Institute; 2005 Sep 21.
15. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 2000;11:939-45.
16. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999;3:1-143.
17. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010;7:312-21.
18. Schroen AT, Petroni G, Wang H, Thielen MJ, Sargent D, Benedetti JK, et al. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials 2011;8:591-600.
19. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-6.